Abstract: The present invention relates to a biomarker panel for determining a molecular subtype of cancer and a method of predicting prognosis of cancer using the panel. The biomarker panel identifies molecular subtypes of tumors by selecting and analyzing only information on tumor cells from single-cell transcriptome data derived from patients with early lung cancer, thereby allowing prediction of the prognosis of lung cancer and prediction of the response to anti-cancer agents. Therefore, the biomarker panel may be used for selecting a treatment regimen.

Abstract: The present invention relates to a graphene oxide complex having attached thereto a structure composed of single-stranded probes, each comprising a nucleic acid complementary to a target nucleic acid and a fluorescent substance. The graphene oxide complex can detect and quantify multiple biomarkers (target nucleic acids) in real time with high sensitivity at low cost without PCR, and thus can easily diagnose most diseases in which multiple biomarkers are involved, and evaluate the effect of drug use.